AI/ML Innovations Inc. Granted Management Cease Trade Order
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) has been granted a Management Cease Trade Order (MCTO) by the British Columbia Securities Commission due to a delay in filing its audited annual financial statements for the year ended April 30, 2024. The MCTO restricts trading in company securities by the CEO and CFO but does not generally affect other shareholders' ability to trade. The company expects to file the required documents by September 15, 2024.
AI/ML Innovations focuses on artificial intelligence and machine learning technologies in digital health and wellbeing. The company has investments in Health Gauge (70% owned), Tech2Heal (22% ownership commitment), and AI Rx Inc. (70% owned).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) ha ricevuto un Ordine di Sospensione della Gestione (MCTO) dalla British Columbia Securities Commission a causa di un ritardo nella presentazione dei suoi bilanci finanziari annuali certificati per l'anno chiuso il 30 aprile 2024. Il MCTO limita il trading dei titoli dell'azienda da parte del CEO e del CFO, ma non influisce generalmente sulla capacità degli altri azionisti di commerciare. L'azienda prevede di presentare i documenti richiesti entro il 15 settembre 2024.
AI/ML Innovations si concentra sulle tecnologie di intelligenza artificiale e apprendimento automatico nella salute digitale e nel benessere. L'azienda ha partecipazioni in Health Gauge (70% di proprietà), Tech2Heal (impegno di proprietà del 22%) e AI Rx Inc. (70% di proprietà).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) ha recibido un Orden de Detención de Gestión (MCTO) por parte de la Comisión de Valores de Columbia Británica debido a un retraso en la presentación de sus estados financieros auditados anuales para el año terminado el 30 de abril de 2024. El MCTO restringe el comercio de los valores de la empresa por parte del CEO y CFO, pero no afecta generalmente la capacidad de otros accionistas para comerciar. La empresa espera presentar los documentos requeridos para el 15 de septiembre de 2024.
AI/ML Innovations se centra en las tecnologías de inteligencia artificial y aprendizaje automático en la salud digital y el bienestar. La empresa tiene inversiones en Health Gauge (70% de propiedad), Tech2Heal (compromiso de propiedad del 22%) y AI Rx Inc. (70% de propiedad).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB)는 2024년 4월 30일로 종료된 회계연도의 감사된 연간 재무제표 제출 지연으로 인해 브리티시컬럼비아 증권위원회로부터 경영 거래 중단 명령(MCTO)을 받았습니다. MCTO는 CEO와 CFO의 회사 증권 거래를 제한하지만, 일반적으로 다른 주주들의 거래 능력에는 영향을 미치지 않습니다. 회사는 2024년 9월 15일까지 필요한 문서를 제출할 계획입니다.
AI/ML Innovations는 디지털 건강 및 웰빙 분야의 인공지능 및 기계 학습 기술에 집중하고 있습니다. 이 회사는 Health Gauge (70% 소유), Tech2Heal (22% 소유 약속) 및 AI Rx Inc. (70% 소유)에 대한 투자를 하고 있습니다.
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) a reçu un Ordre d'Interdiction de Négociation de Management (MCTO) de la part de la Commission des valeurs mobilières de la Colombie-Britannique en raison d'un retard dans le dépôt de ses états financiers annuels audités pour l'exercice clos le 30 avril 2024. Le MCTO limite la négociation des titres de la société par le PDG et le directeur financier, mais n'affecte généralement pas la capacité des autres actionnaires à négocier. La société prévoit de soumettre les documents requis d'ici le 15 septembre 2024.
AI/ML Innovations se concentre sur les technologies d'intelligence artificielle et d'apprentissage automatique dans le domaine de la santé numérique et du bien-être. L'entreprise a des investissements dans Health Gauge (70% de propriété), Tech2Heal (engagement de propriété de 22%) et AI Rx Inc. (70% de propriété).
AI/ML Innovations Inc. (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB) hat von der British Columbia Securities Commission einen Management Cease Trade Order (MCTO) aufgrund einer Verzögerung bei der Einreichung ihrer geprüften Jahresfinanzberichte für das am 30. April 2024 endende Geschäftsjahr erhalten. Der MCTO beschränkt den Handel von Unternehmenswertpapieren durch den CEO und CFO, hat jedoch grundsätzlich keine Auswirkungen auf die Handelsmöglichkeiten anderer Aktionäre. Das Unternehmen erwartet, die erforderlichen Dokumente bis zum 15. September 2024 einzureichen.
AI/ML Innovations konzentriert sich auf künstliche Intelligenz und maschinelles Lernen Technologien im digitalen Gesundheits- und Wellnessbereich. Das Unternehmen hat Beteiligungen an Health Gauge (70% im Besitz), Tech2Heal (22% Eigentumsverpflichtung) und AI Rx Inc. (70% im Besitz).
- Company expects to file required financial documents by September 15, 2024
- MCTO does not generally affect non-insider shareholders' ability to trade
- Failure to file audited annual financial statements by the August 28, 2024 deadline
- Management Cease Trade Order issued, restricting trading by CEO and CFO
- Company in default of obligations under National Instrument 51-102
VICTORIA, BC / ACCESSWIRE / August 29, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, did not file its audited annual financial statements, management's discussion and analysis and related CEO and CFO certifications for the financial year ended April 30, 2024 (the "Required Filings") by the filing deadline of August 28, 2024, and as a result is in default of its obligations under Part 4 of National Instrument 51-102 Continuous Disclosure Obligations.
As previously announced on August 23, 2024 (the "Announcement"), the Company applied to the British Columbia Securities Commission (the "BCSC") for a management cease trade order (the "MCTO"), which would restrict all trading in securities of the Company, whether direct or indirect, by the Chief Executive Officer and Chief Financial Officer of the Company. The BCSC issued the MCTO on August 29, 2024. The MCTO does not generally affect the ability of shareholders who are not insiders of the Company to trade their securities.
The Company and its auditor continue to work diligently toward completing the Required Filings and expect to remedy the default by filing the Required Filings on or before September 15, 2024.
The Company confirms that since the date of the Announcement: (i) there has been no material change to the information set out in the Announcement that has not been generally disclosed; (ii) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the "alternative information guidelines" under National Policy 12-203 Management Cease Trade Orders ("NP 12-203") and issue bi-weekly default status reports for so long as the delay in filing the Required Filings is continuing, each of which will be issued in the form of a news release; (iii) there has not been any other specified default by the Company under NP 12-203; (iv) the Company is not subject to any insolvency proceedings; and (v) there is no material information concerning the affairs of the Company that has not been generally disclosed.
For more information about AI/ML Innovations:
For detailed information please see AI/ML's website or the Company's filed documents at www.sedarplus.ca.
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.
About AI/ML Innovations Inc. https://aiml-innovations.com/
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (
Certain statements in this news release are "forward-looking statements", which reflect management's expectations regarding the MCTO and timing of the filing of the Required Filings. All statements other than statements of historical fact contained in this news release are forward-looking statements. Such forward-looking statements involve risks and uncertainties, as they reflect management's current beliefs and are based on information currently available to management. Actual results may differ materially from those anticipated in the statements made. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The forward-looking statements are made as of the date of this news release and the Company assumes no obligation to update or revise them to reflect new events or circumstances except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by the Company with the securities regulatory authorities, available at www.sedarplus.ca.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: AI/ML Innovations, Inc.
View the original press release on accesswire.com
FAQ
Why was AI/ML Innovations Inc. (AIMLF) granted a Management Cease Trade Order?
When does AI/ML Innovations Inc. (AIMLF) expect to file the required financial documents?
How does the Management Cease Trade Order affect AI/ML Innovations Inc. (AIMLF) shareholders?
What are the main business focus areas of AI/ML Innovations Inc. (AIMLF)?
